|
1. van der Steeg, W. et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I. J Am Coll Cardiol. 2008 51:634-42.
2. van der Steeg, W. et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med. 2007;146:640-8.
3. El Harchaoui, K. et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49:547-53.
4 van der Steeg, W. et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I. J Am Coll Cardiol. 2008 Feb 12;51:634-42.
5. Rasouli M, Mohseni Kiasari A. Interactions of lipoprotein(a) with diabetes mellitus, apolipoprotein B and cholesterol enhance the prognostic values for coronary artery disease. Clin Chem Lab Med. 2008;46(5):667-73.
6. Pitsavos, C. et al. Prevalence and determinants of coronary artery disease in males and females with familial combined hyperlipidaemia. Atherosclerosis. 2008;199:402-7.
7. Sabatine, M et al.Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007:2463-9.
8. Schmidt, E. et al.Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis. 2008 196:420-4.
9. Dong, X. et al. Impaired fasting glucose and the prevalence and severity of angiographic coronary artery disease in high-risk Chinese patients. Metabolism. 2008;57(1):24-9.
10. Miyazaki, T. et al. Insulin response to oral glucose load is associated with coronary artery disease in subjects with normal glucose tolerance. J Atheroscler Thromb. 2008 15:6-12. See also M. Takeno et al. Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: potential association with C-reactive protein. Circ J. 2008 72:415-9.
11. Kasai, The relationship between the metabolic syndrome defined by various criteria and the extent of coronary artery disease. Atherosclerosis. 2008 197(2):944-50.
12. Guo H, Lee JD, Ueda T, Cheng J, Shan J, Wang J. Hyperhomocysteinaemia & folic acid supplementation in patients with high risk of coronary artery disease. Indian J Med Res. 2004 119(1):33-7.
13. Lee, B. et al. Folic acid and vitamin B12 are more effective than vitamin B6 in lowering fasting plasma homocysteine concentration in patients with coronary artery disease. Eur J Clin Nutr. 2004;58(3):481-7. See also Guo, H et al. Homocysteine levels in patients with early coronary artery stenosis and high risk factors. Jpn Heart J. 2003 Nov;44(6):865-71 and Lee BJ, Lin PT, Liaw YP, Chang SJ, Cheng CH, Huang YC. Homocysteine and risk of coronary artery disease: Folate is the important determinant of plasma homocysteine concentration. Nutrition. 2003 Jul-Aug;19(7-8):577-83.
14. Nygard, O et al. Total homocysteine and cardiovascular disease. J Intern Med. 1999 Nov;246(5):425-54.
15. Cheng, C. et al. Plasma pyridoxal 5'-phosphate and high-sensitivity C-reactive protein are independently associated with an increased risk of coronary artery disease. Nutrition. 2008 24:239-44.
16. Chonchol M, and Nielson C. Hemoglobin levels and coronary artery disease. Am Heart J. 2008, 155:494-8.
17. deFilippi, C et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003 290(3):353-9. and deFilippi Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: angiographic correlates and long-term clinical outcomes. J Am Coll Cardiol. 2000;35:1827-34.
18. de Filippi, C. et al. Frequency and cause of cardiac troponin T elevation in chronic hemodialysis patients from study of cardiovascular magnetic resonance. Am J Cardiol. 2007;100(5):885-9. See also de Filippi, C. et al. Diagnostic accuracy, angiographic correlates and long-term risk stratification with the troponin T ultra sensitive Rapid Assay in chest pain patients at low risk for acute myocardial infarction. Eur Heart J. 1998 Nov;19
19. Gurbel, P. et al. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J. 2008;155:56-61.
20. Ye, Z. et al. Baseline serum matrix metalloproteinase-9 level predicts long-term prognosis after coronary revascularizations in stable coronary artery disease. Clin Biochem. 2008 41(4-5):292-8.
21. Stefanescu A, Braun S, Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J. 2008 155:356-60.
22. Ndrepepa, G. et al. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest. 2008 38:90-6.
23. Stefanescu A, Braun S, Ndrepepa G, Koppara T, Pavaci H, Mehilli J, Schömig A, Kastrati A. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J. 2008, 155:356-60.
|